Form 4: Summit Therapeutics Executive Robert Duggan Acquires Stock Options Through Amendment

Robert Duggan, Co-CEO of Summit Therapeutics, acquired stock options through an amendment converting performance-based options to time-based options.

Summary

• Robert W. Duggan, Co-Chief Executive Officer of Summit Therapeutics Inc., filed a Form 4 on May 1, 2025, reporting changes in beneficial ownership.
• The filing indicates that Duggan acquired stock options on April 29, 2025, through an amendment that converted performance-based stock options to time-based stock options.
• These options include 1,040,000 shares at an exercise price of $1.06, 400,000 shares at $1.29, and 9,590,558 shares at $1.68.
• The shares underlying the options vest as follows: 50% vested on April 29, 2025, and the remaining 50% vest in three equal annual installments starting October 13, 2025.
• Duggan disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard regulatory filing related to stock option amendments.

Positives

• The conversion of performance-based options to time-based options provides Duggan with a more predictable vesting schedule.

Management Comments

• The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• Shareholders may view the vesting schedule change as a way to retain executive talent.

Key Dates

Keywords

stock options, Summit Therapeutics, beneficial ownership, Form 4, Robert Duggan, Co-CEO